Answers are grounded in this paper and cite their sources.
Purpose Thumb carpometacarpal osteoarthritis (CMC1-OA) is a prevalent degenerative condition with limited effective nonsurgical treatments. Curcumin has shown anti-inflammatory effects and clinical benefit in lower-extremity osteoarthritis but has not been evaluated in hand osteoarthritis. This study evaluated the efficacy of oral curcumin supplementation in symptomatic CMC1-OA. Methods A prospective, double-blind, randomized, placebo-controlled crossover trial enrolled adults aged ≥40 years with radiographically confirmed CMC1-OA. All participants received a thumb carpometacarpal orthosis and home exercise program. Participants were randomized 1:1 to curcumin (500 mg twice daily) or placebo for 8 weeks, followed by a 2-week washout and crossover for an additional 8 weeks. The primary outcome was change in visual analog scale pain. Secondary outcomes included grip and pinch strength, Kapandji score, Patient-Reported Outcomes Measurement Information System Global Health 10-item questionnaire, Single Assessment Numeric Evaluation, Australian/Canadian Osteoarthritis Hand Index, and Disabilities of the Arm, Shoulder, and Hand. Assessments were performed at baseline and after each treatment phase. Results Twenty participants (14 women; mean age 64.3 years) completed the study with 100% adherence. No statistically significant difference in visual analog scale pain was observed between curcumin and placebo. Secondary outcomes, including Patient-Reported Outcomes Measurement Information System Global Health 10-item questionnaire, Australian/Canadian Osteoarthritis Hand Index, Disabilities of the Arm, Shoulder, and Hand, grip strength, pinch strength, and Kapandji score, similarly showed no significant differences. A decrease in right-hand Single Assessment Numeric Evaluation scores occurred with curcumin, whereas placebo was associated with small bilateral Single Assessment Numeric Evaluation improvements, suggesting a nontreatment-specific effect. No adverse events or clinically significant laboratory changes occurred. Conclusions Oral curcumin (1,000 mg daily for 8 weeks) did not improve pain, function, or strength in CMC1-OA. Although well tolerated, these findings do not support curcumin as an effective standalone nonsurgical treatment at this dose and duration. Clinical relevance Curcumin, at the dose and duration studied, does not provide meaningful clinical benefit for thumb carpometacarpal osteoarthritis and should not be recommended as a standalone nonsurgical treatment.
No takes yet. Share an insight, caveat, or question.
Zilinskas et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: